The symptoms of the flu are familiar: fever, chills, cough, congestion, feeling very, very tired. If you're a healthy adult under 65, you'll most likely recover in a week or two.
But for those older than 65, things can get worse fast, says Dr. H. Keipp Talbot, an infectious disease specialist at Vanderbilt University.
"It's not [just] a cold, it's not the chills, it's not a runny nose," she says. "For many people it can be hospitalization, pneumonia, worsening heart failure." Flu complications like these hospitalize more than 200,000 older adults every year, and thousands die.
"As we age, so does our immune system," says Talbot. On top of that, age-related health problems increase susceptibility. These may include "high blood pressure, diabetes, heart disease," Talbot says. "And so we're at a much greater risk of having hospitalizations or pneumonia if we develop influenza as we age."
A new supersize vaccine could lower that risk. The Fluzone High-Dose influenza vaccine was approved by the Food and Drug Administration for use four years ago, after it proved safe and effective at boosting the number of antibodies to fight the flu.
But the FDA wanted to know if it actually prevented people from getting sick, so the agency asked the manufacturer to do another study to get at that issue.
Talbot headed the study, published just before the start of this year's flu season. She divided 32,000 people older than 65 into two groups. One group received the standard vaccine while the other got a dose that was four times higher.
"We found that the high dose was 24 percent more effective than the standard dose at preventing influenza — any influenza, no matter what circulated, no matter what strain it was," Talbot says.
Recipients who got the higher dose were more likely to report that their arms were a little sore afterward, but there were no other serious side effects.
The Centers for Disease Control and Prevention, which issues guidance about how vaccines should be used, is still evaluating whether to preferentially recommend the higher dose for older people.
At the other end of the age spectrum, this is the first year that CDC officials have recommended that children between the ages of 2 and 8 get their flu vaccine in the form of a nasal spray rather than a shot.
"The influenza virus can change genetically and be slightly different," says Dr. William Schaffner, a professor of preventive medicine at Vanderbilt University Medical School. "And it would appear as though the mist provides broader coverage against these altered strains that might be around."
Schaffner says the mist is made with a weakened version of live flu virus, so may more closely mimic a real infection than other versions and perhaps boost the body's immune response more.
He also notes that some concerns have emerged in recent days about whether the mist vaccine was truly effective last winter against the common H1N1 flu strain. Health officials are still looking into why that might be, he says; inadequate refrigeration of some of the vaccine shipped the previous summer might be to blame.
Until more is known, the American Academy of Pediatrics is holding off on suggesting that the mist is more effective than the shot for this age group. But, like the CDC, the pediatricians group emphasizes that either flu vaccine is much better than none.
For now, says pediatrician Henry Bernstein, a member of the academy's vaccine committee, "healthy children ages 2 through 8 years may be immunized with either the shot or the intranasal vaccine. There is no preference for one versus the other."
Whether you choose mist or injection, federal guidelines urge that everyone over the age of 6 months get vaccinated against the flu — especially pregnant women, says Schaffner.
"The protection that the woman builds up passes through the placenta and goes into the newborn baby and helps protect that newborn baby during the first six months of its life when the baby is too young to be vaccinated itself," he says. "And so there's a double reason to vaccinate pregnant women."
This year, there appears to be a rise in the number of people getting their flu vaccine early, says Schaffner — maybe because of increased concern about an unrelated illness, Ebola.
Of course, the flu vaccine has no effect on Ebola, and Ebola isn't circulating in the United States. But, he says, if misplaced worries about a rare illness mean more people are getting vaccinated against the far more common flu virus — all the better.
Transcript
ROBERT SIEGEL, HOST:
Every flu season health officials estimate 1 in 5 Americans will get the virus. This year there are new federal guidelines and developments in vaccines and as NPR's Patti Neighmond reports, they could strengthen immunity for young children and people over 65, who are most susceptible.
PATTI NEIGHMOND, BYLINE: Flu symptoms are familiar - fever, chills, cough, congestion, feeling very, very tired. If you're a healthy adult under 65 you'll likely recover in a week or two, but for those over 65 things can get worst fast, says Dr. Keipp Talbot, an infectious disease specialist at Vanderbilt University Medical Center.
KEIPP TALBOT: It's not a cold. It's not the chills. It's not a runny nose, but for many people it can be hospitalization and pneumonia, worsening heart failure.
NEIGHMOND: Complications like this hospitalize more than 200,000 older adults every year and thousands die.
TALBOT: As we age so does our immune system.
NEIGHMOND: On top of that, age-related health problems increase susceptibility.
TALBOT: High blood pressure, diabetes, heart disease and so we're at much greater risk of having hospitalizations or pneumonia if we develop influenza as we age.
NEIGHMOND: But a new supersized vaccine could change things. Fluzone High-Dose was approved by the Food and Drug Administration four years ago. It proved safe and effective, boosting the number of antibodies to fight the flu, but the FDA wanted to know if it actually prevented people from getting sick. It asked the manufacturer to do another study.
Keipp Talbot headed the study. Thirty-two thousand people over 65 were divided into two groups. One received the standard vaccine, the other got a dose four times higher.
TALBOT: We found that the high dose was 24 percent more effective than the standard dose at preventing influenza, any influenza, no matter what circulated, no matter what strain it was.
NEIGHMOND: People said their arms were a little more sore with the high dose, but there were no other serious side effects. As it is now the Centers for Disease Control and Prevention, which issues guidance about how vaccines should be used, is evaluating whether to recommend the high dose for older people. At the other end of the age spectrum, this is the first flu season CDC officials say children between the ages of 2 and 8 should get the vaccine in nasal spray form instead of the shot.
Dr. William Schaffner with Vanderbilt University Medical School.
WILLIAM SCHAFFNER: The influenza virus can change genetically and be slightly different and it would appear as though the mist provides broader coverage against these altered strains that might be around.
NEIGHMOND: Schaffner says the mist is made with live flu virus and mimics a real infection, thereby boosting the body's immune response, but recently there have been concerns about whether it was truly effective last year against the common H1N1 flu strain. Health officials are investigating. Until more is known, pediatrician Henry Bernstein with the American Academy of Pediatrics says there should be no preference for the mist.
HENRY BERNSTEIN: Healthy children ages 2-8 years may be immunized with either the shot or the intranasal vaccine. There is no preference for one versus the other.
NEIGHMOND: Whether mist or injection, federal guidelines say everyone over the age of 6 months should get vaccinated against the flu - especially, says William Schaffner, pregnant women.
SCHAFFNER: The protection that the woman builds up passes through the placenta and goes into the newborn baby and helps protect that newborn baby during the first 6 months of its life when the baby is too young to be vaccinated itself and so there's a double reason to vaccinate pregnant women.
NEIGHMOND: This year, Schaffner says, there appears to be a rise in the number of people getting their flu vaccine early. That may be due to worries about Ebola. Of course, the flu vaccine has no effect on Ebola and Ebola isn't circulating in the U.S. but if it means more people are getting vaccinated against the far more common flu virus then Schaffner says, all the better. Patti Neighmond, NPR News. Transcript provided by NPR, Copyright NPR.
300x250 Ad
300x250 Ad